for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boryung Pharmaceutical Co., Ltd

003850.KS

Latest Trade

15,300.00KRW

Change

-300.00(-1.92%)

Volume

266,381

Today's Range

15,200.00

 - 

15,650.00

52 Week Range

9,490.00

 - 

16,700.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
15,600.00
Open
15,450.00
Volume
266,381
3M AVG Volume
6.89
Today's High
15,650.00
Today's Low
15,200.00
52 Week High
16,700.00
52 Week Low
9,490.00
Shares Out (MIL)
42.04
Market Cap (MIL)
676,260.00
Forward P/E
18.61
Dividend (Yield %)
--

Latest Developments

More

S.Korea's Boryung Pharm Says Co-CEO Kim Eun-Sun Resigns For Personal Reason, Appoints An Jae-Hyun As New Co-CEO

Boryung Pharm to buy back shares at 5.57 bln won

Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boryung Pharmaceutical Co., Ltd

Boryung Pharmaceutical Co.,Ltd. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company’s products include antibiotics, dermatology drugs, cardiovascular drugs, antineoplastics, antiemetics, urology drugs, gastrointestinal drugs, antipyretic drugs, analgesics, anti-inflammatory drugs, amino acids injections, dialysis drugs, antidiabetics, central nervous system (CNS) drugs, vaccines and others. It also provides active pharmaceutical ingredients (API) products, including doxorubicin hydrochloride, epirubicin hydrochloride, captopril, alacepril, nitrendipine, fluconazole, ondansetron hydrochloride, tamsulosin hydrochloride, glimepiride, torsemide and others.

Industry

Biotechnology & Drugs

Contact Info

Boryung Bldg.

136, Changgyeonggung-ro, Jongno-gu

+82.2.7088000

http://www.boryung.co.kr

Executive Leadership

Eun Seon Kim

Chairman of the Board

Seung Ho Kim

Chairman

Jae Hyeon Ahn

Co-Chief Executive Officer, Director

Sam Su Lee

Co-Chief Executive Officer, Director

Yong Gwan Jeon

Vice President

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, KRW)

2016

0.4K

2017

0.4K

2018

0.5K

2019(E)

0.5K
EPS (KRW)

2016

131.200

2017

266.800

2018

483.000

2019(E)

822.000
Price To Earnings (TTM)
19.52
Price To Sales (TTM)
1.36
Price To Book (MRQ)
2.29
Price To Cash Flow (TTM)
13.98
Total Debt To Equity (MRQ)
34.05
LT Debt To Equity (MRQ)
26.76
Return on Investment (TTM)
9.67
Return on Equity (TTM)
6.86

Latest News

Latest News

BRIEF-Boryung Pharm Agrees To Terminate $70 Mln Worth Contract With Novartis' Unit In Southeast Asia

* AGREES TO TERMINATE 85 BILLION WON ($70.09 million) WORTH CONTRACT WITH NOVARTIS' UNIT IN SOUTHEAST ASIA Source text for Eikon: https://bit.ly/2NwTDEF Further company coverage: ($1 = 1,212.6600 won)

BRIEF-Boryung Pharm to buy back shares at 5.57 bln won

* Says it will repurchase 100,000 common shares worth 5.57 billion won

BRIEF-Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

* SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA

BRIEF-Boryung Pharm signs contract worth 70.25 bln won

* Says it signed 70.25 billion won contract to provide products

BRIEF-Boryung Pharm signs contract worth 42.18 bln won

* Says it signed a 42.18 billion won contract with Kiara Health(PTY) Ltd to provide products

BRIEF-Boryung Pharm to pay annual dividend as 200 won/share for FY 2016

* Says it will pay annual cash dividend as 200 won/share for FY 2016, to shareholders of record on Dec. 31, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up